Radiomics signatures have been described that are associated with tumour features such as the degree of tumour mutational burden and presence of tumour-infiltrating lymphocytes both considered to be predictive of tumour response to anti-PDL1/PD1 therapy.72 The gene discussed is CD274; the disease is neoplasm.